-+ 0.00%
-+ 0.00%
-+ 0.00%

NeuroSense Therapeutics effects 1-for-20 reverse stock split on Sept. 14, 2026

PUBT·09/09/2026 20:31:01
Listen to the news
NeuroSense Therapeutics effects 1-for-20 reverse stock split on Sept. 14, 2026
  • NeuroSense Therapeutics will execute a 1-for-20 reverse stock split of its ordinary shares.
  • Post-split trading on the Nasdaq Capital Market is set to begin on Sept. 14, 2026.
  • Issued shares are expected to fall to 1,896,902 from 37,938,036, subject to rounding of fractional shares.
  • Fractional shares will be rounded up to the nearest whole share.
  • Outstanding warrants and options will be adjusted proportionately for share count and exercise price.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-098414), on September 09, 2026, and is solely responsible for the information contained therein.